<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549012</url>
  </required_header>
  <id_info>
    <org_study_id>blood loss after CS</org_study_id>
    <nct_id>NCT04549012</nct_id>
  </id_info>
  <brief_title>Determination of Blood Loss After CS</brief_title>
  <official_title>Tranexamic Acid Plus Oxytocin Versus Oxtocin Only in Reducing Blood Loss After Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing betweeen tranexamic acid plus oxytocin and oxytocin alone in their efficacy in&#xD;
      reducing blood loss following CS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      tranexamic acid plus oxytocin versus oxytocin only in reducing blood loss following CS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group (A) will receive oxytocin only Group (B)will receive oxytocin plus tranexamic acid</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>women will be given serial number ,randomization will be done through a computer generated system</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>amount of blood loss</measure>
    <time_frame>baseline</time_frame>
    <description>comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maternal and neonatal complication</measure>
    <time_frame>baseline</time_frame>
    <description>blood transfusion ,surgical injuries ,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Effect of Drug</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive tranexamic acid plus oxytocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS</description>
    <arm_group_label>group B</arm_group_label>
    <other_name>oxytocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin</description>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age : 20-40 year&#xD;
&#xD;
               -  2- Gestational age is between 37-41weeks&#xD;
&#xD;
        3- Delivery by uncomplicated elective CS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1- Risk factors for uterine atony such as polyhydramnios or fetal macrosomia. 2-&#xD;
             Grandmultiparity 3- Past history of postpartum hemorrhage either atonic or traumatic&#xD;
             4- Previous history of retained placenta 5- Pre-eclampsia or gestational hypertension/&#xD;
             Maternal DM 6- Abnormal placentation 7- Contraindications to the use of tranexamic&#xD;
             acid 8- Hypersensitivity to tranexamic acid. 9- Women receiving anticoagulant therapy.&#xD;
             10- having underlying disease (heart, liver, kidney, pulmonary, etc.),&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>noha abu shata</last_name>
    <phone>01000287839</phone>
    <email>mhmwdnhy44@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>tamer Borg</last_name>
    <phone>01001457437</phone>
    <email>tamerborg1975@gmail.com</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Noha Mahmoud Abu Shata</investigator_full_name>
    <investigator_title>egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

